Similar articles

• Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.

  Karp JE, Lancet JE. Karp JE, et al. Cancer Invest. 2007 Sep;25(6):484-94. doi: 10.1080/07357900701359437. Cancer Invest. 2007. PMID: 17882662 Review.
• Clinical trials referral resource. Current clinical trials of bortezomib.

  Wright JJ, Zerivitz K, Schoenfeldt M. Wright JJ, et al. Oncology (Williston Park). 2003 May;17(5):677-80, 683-6, 691-2. Oncology (Williston Park). 2003. PMID: 12800794 No abstract available.
• Facilitating patient-centered cancer research and a new era of drug discovery.

  Niederhuber JE. Niederhuber JE. Oncologist. 2009 Apr;14(4):311-2. doi: 10.1634/theoncologist.2009-0051. Epub 2009 Apr 13. Oncologist. 2009. PMID: 19365096 No abstract available.
• [Development for and clinical trials of molecular targeting drugs].

  Takashima A, Fukuda H, Shibata T. Takashima A, et al. Gan To Kagaku Ryoho. 2010 May;37(5):822-7. Gan To Kagaku Ryoho. 2010. PMID: 20524257 Japanese. No abstract available.
• Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.

  Douer D, Tallman MS. Douer D, et al. J Clin Oncol. 2005 Apr 1;23(10):2396-410. doi: 10.1200/JCO.2005.10.217. J Clin Oncol. 2005. PMID: 15800332 Review.